Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Engelhardt

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Nature Communications|April 11, 2017
Determining the bacterial cell biology of PlanctomycetesChristian Boedeker, Margarete Schüler, Greta Reintjes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2024
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLCEun Ji Lee, Seung Yeon Oh, You Won Lee, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Journal of Medicinal Chemistry|August 27, 2025
Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft ModelJames C Tarr, Kyuok Jeon, Nagarathanam Veerasamy, et al.
Journal of Medicinal Chemistry|August 5, 2024
Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent <i>In Vivo</i> Activities in Mouse Models of Hematological and Solid TumorsJames C Tarr, James M Salovich, Martin Aichinger, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Annals of Neurology|December 26, 2021
Variants in Mitochondrial ATP Synthase Cause Variable Neurologic PhenotypesMichael Zech, Robert Kopajtich, Katja Steinbrücker, et al.
Nature Cancer|July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signalingBirgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Nature Communications|April 11, 2017
Determining the bacterial cell biology of PlanctomycetesChristian Boedeker, Margarete Schüler, Greta Reintjes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2024
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLCEun Ji Lee, Seung Yeon Oh, You Won Lee, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Journal of Medicinal Chemistry|August 27, 2025
Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft ModelJames C Tarr, Kyuok Jeon, Nagarathanam Veerasamy, et al.
Journal of Medicinal Chemistry|August 5, 2024
Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent <i>In Vivo</i> Activities in Mouse Models of Hematological and Solid TumorsJames C Tarr, James M Salovich, Martin Aichinger, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Annals of Neurology|December 26, 2021
Variants in Mitochondrial ATP Synthase Cause Variable Neurologic PhenotypesMichael Zech, Robert Kopajtich, Katja Steinbrücker, et al.
Nature Cancer|July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signalingBirgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Pageof 5